Patent intelligence · US
US 11149047
Aryl imidazoles for treatment of cancer
Aryl imidazoles for treatment of cancer
Patent details — US 11149047
- Jurisdiction
- US
- Status
- granted
- Grant date
- Oct 19, 2021
- Expiration
- Oct 14, 2041
- Applicant
- APTOSE BIOSCIENCES INC.
- Claims
- 23
- CPC classes
- A61K, A61K31/4745, A61K31/517, A61K31/555
Quick answer
US 11149047 (Aryl imidazoles for treatment of cancer) is held by APTOSE BIOSCIENCES INC.. Status: granted. Granted Oct 19, 2021. Expires Oct 14, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- APTOSE BIOSCIENCES INC.
- Grant date
- Expiration
- Claims
- 23
- CPC classes
- A61K, A61K31/4745, A61K31/517, A61K31/555, A61K45/06, A61P
More from APTOSE BIOSCIENCES INC.
Related pharmaceutical patents in our USPTO index.
-
US 11279703
Fused pyrimidine compounds as BRD4 and JAK2 dual inhibitors and methods for use thereof
granted -
US 11104957
Compositions and methods for treating cancers
granted -
US 10080739
Aryl imidazoles and their use as anti-cancer agents
granted -
US 9567643
Compositions and methods for treating cancers
granted -
US 8987305
2,4,5-trisubstituted imidazoles and their use as anti-microbial agents
granted -
US 8969372
Aryl imidazoles and their use as anti-cancer agents
granted
Frequently asked questions
What is US patent 11149047?
US 11149047 (Aryl imidazoles for treatment of cancer) is held by APTOSE BIOSCIENCES INC.. Status: granted. Granted Oct 19, 2021. Expires Oct 14, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11149047?
APTOSE BIOSCIENCES INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 7 pharmaceutical patents for this assignee.
When does US 11149047 expire?
Our index shows an expiration date of Oct 14, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.